The transition from the Medical Device Directive (MDD) to the Medical Device Regulation (EU MDR 2017/745) has been one of the most disruptive regulatory overhauls in global healthcare history. Recognizing the severe backlog of Notified Bodies (NBs) and the threat of critical medical device shortages, the European Parliament extended transition timelines. However, this extension is not a reason to delay.

To qualify for the transition extensions, manufacturers must meet strict prerequisites, including establishing a compliant Quality Management System (QMS) as per EU MDR Article 10(9) and filing formal applications with Notified Bodies. In 2026, the margin for delay has vanished.

"The extensions are a lifeline, not a vacation. Manufacturers who fail to finalize their technical files and sign contracts with Notified Bodies risk losing market access entirely as legacy certificates expire."

Upgrading to EU MDR: Five Core Pillars of Compliance

Adapting your device technical files from MDD to MDR requires addressing five fundamental updates:

• 1. Enhanced Clinical Evaluation Reports (CERs): The MDR demands significantly more robust clinical evidence. Relying purely on equivalence is now extremely difficult without direct access to the technical data of the equivalent device. You must generate more PMCF (Post-Market Clinical Follow-up) data.
• 2. Stringent Post-Market Surveillance (PMS): Reactive complaint handling is no longer sufficient. Proactive PMS planning, continuous monitoring of real-world device performance, and regular Periodic Safety Update Reports (PSURs) are mandatory.
• 3. UDI and EUDAMED Integration: Unique Device Identification (UDI) implementation and continuous data feeding into the EUDAMED database are central to the MDR's transparency goals.
• 4. Economic Operator Obligations: The responsibilities of Importers, Distributors, and Authorized Representatives (EC REPs) are now legally binding and subject to intense scrutiny. Agreements must be completely overhauled.
• 5. Supply Chain Control: Complete traceability and rigorous control over critical suppliers and outsourced manufacturing processes must be demonstrably integrated into the QMS.

The post Demystifying EU MDR Compliance: Key Steps for CE Marking in 2026 appeared first on HL Associates.

Under the EU MDR, the Clinical Evaluation Report (CER) is no longer a static document. It is the beating heart of your technical file. Notified bodies are scrutinizing the methodology used in literature searches and the robustness of the data linking clinical benefits to safety.

State of the Art (SOTA)

A frequent pitfall is failing to establish a comprehensive SOTA. Your CER must analyze alternative treatments, competitor devices, and the current clinical guidelines to prove that your device's risk-benefit profile remains acceptable in the modern clinical landscape.

The post Writing Bulletproof Clinical Evaluation Reports (CER) for EU MDR appeared first on HL Associates.